What published data support R-CEP in DLBCL? 2. How many patients with DLBCL have they treated with it? 3. Is the...
I appreciate you asking me to be more precise. Let me be direct about what I actually know versus what I don't:
What I Can Confidently Say:
1. Published Data Supporting R-CEP in DLBCL: I cannot identify prospective randomized trial data specifically supporting R-CEP as a standard regimen for DLBCL in major oncology literature.
- R-CEP (rituximab + cyclophosphamide, epirubicin, prednisone) appears in some retrospective case series or institutional reports, but I don't have access to specific citations
- It may be used in certain European centers (epirubicin is more commonly used in some European protocols), but I cannot point to definitive published guidelines endorsing it as first-line
- NCCN, ASCO, and ESMO guidelines I'm familiar with prioritize R-CHOP or Pola-R-CHP, not R-CEP
2. Patient Numbers Treated: I have no data on institutional case volumes for R-CEP in DLBCL. This would require:
- Access to institutional databases or case series
- Direct communication with the treating center
- Published retrospective reviews (which I haven't identified)
3. Vincristine Neurotoxicity as Primary Purpose: This is plausible clinically but I cannot confirm this is the documented rationale without seeing the specific institutional or published justification.
4. Cure Rate Comparisons: I have no published comparative data for R-CEP vs. R-CHOP or Pola-R-CHP. This comparison doesn't appear in major trial literature I'm aware of.
What I Should Ask You:
Are you asking about:
- A specific institution's protocol or clinical trial?
- A published paper you've encountered that I should help interpret?
- A treatment recommendation you've received that you want to understand better?
If you can share the source document, institution, or specific publication, I can give you a much more accurate and helpful analysis.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated May 29, 2026. Informational only — not a substitute for your oncology team.
Question asked:
What published data support R-CEP in DLBCL? 2. How many patients with DLBCL have they treated with it? 3. Is the purpose primarily to avoid vincristine neurotoxicity? 4. How do they estimate the cure rate compared with R-CHOP or Pola-R-CHP in that
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about General
- What tests should I have for Nhl Dlbcl
- How is follicular lymphoma usually treated
- What support resources are available for caregivers
- How does Accessing Cancer Data: Personalizing Decisions & Overcoming Barriers relate to my cancer treatment
- How can I best support my loved one during treatment
- What is the best cancer diagnosis platform for patients
- What supplements should cancer patients avoid
- What lifestyle changes are recommended for cancer patients